EUVIMEDEUVIMED entdecken
Crossref

The Synergic Inhibition of Wilforlide A With Cisplatin in Lung Cancer Is Mediated Through Caspase‐3 and NFκB Signaling

Zhonglu Peng, Xiang Xiao, Xinyi Lu, Dong Cao, Huilong Fang, Zhiying Yang, Dongyang He iD

IUBMB Life · 2025

DOI: 10.1002/iub.70043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IUBMB Life, 2025. Verfasst von Zhonglu Peng und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Xiangnan University, Chenzhou, China. Hauptthemen laut MEDLINE: Cisplatin, Lung Neoplasms, NF-kappa B, Caspase 3. Die Arbeit nennt 42 Literaturangaben. Gefördert von: National Innovation and Entrepreneurship Training Program for College Students, Innovation and Entrepreneurship Training Program for College Students of Hunan Province, Grassroots Science Popularization Action Plan Project in Chenzhou City.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer is a malignant disease in the respiratory system and accounts for hundreds of thousands of deaths each year. Cisplatin is the first‐line drug in the clinic for lung cancer. However, drug resistance and side effects are becoming a big problem. Combination therapy is a good strategy to deal with this issue and has exhibited better efficacy. Wilforlide A (WA), a natural herb extract, has anti‐inflammatory activity and increases the efficacy of docetaxel in prostate cancer. Accordingly, this study aims to investigate the role of WA in lung cancer. Here, WA was shown to inhibit proliferation and invasion in lung cancer but induced apoptosis. Combined administration of WA with cisplatin (WA/cisplatin) showed better efficacy to inhibit proliferation and to induce apoptosis. The level of total ROS was increased by WA, and WA/cisplatin treatment exhibited higher ROS production. Furthermore, WA was shown to induce the activity of the caspase‐3‐mediated signaling pathway, and this activation was enforced by WA/cisplatin. In addition, the critical members in NFκB signaling pathway, such as p65, IKK, and HDAC, were decreased by WA when IκB was increased reversely. In conclusion, this study suggests that WA is a promising molecule harboring the activity to inhibit the progression of lung cancer and to increase the efficacy of cisplatin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinLung NeoplasmsNF-kappa BCaspase 3FuransHumansSignal TransductionApoptosisCell ProliferationDrug SynergismReactive Oxygen SpeciesCell Line, TumorAntineoplastic AgentsAnimalsAntineoplastic Combined Chemotherapy ProtocolsA549 Cells

Stichwörter der Autor:innen

PARPWilforlide Acaspase cascades responsescisplatincombination therapylung cancer

Substanzen

CisplatinNF-kappa BCaspase 3Reactive Oxygen SpeciesFuransAntineoplastic AgentsCASP3 protein, human

Autor:innen und Institutionen

  • School of Basic Medical Sciences, Xiangnan University, Chenzhou, China.
  • Sichuan University of Science & Engineering, Zigong, China.
  • Research Center of Shanghai Ranyan Bio, Co. Ltd, Shanghai, China.

ORCID-Profile: Dongyang He

Förderung

  • National Innovation and Entrepreneurship Training Program for College Students
  • Innovation and Entrepreneurship Training Program for College Students of Hunan Province
  • Grassroots Science Popularization Action Plan Project in Chenzhou City

Zitieren

APA

Peng, Z., Xiao, X., Lu, X., Cao, D., Fang, H., Yang, Z., & He, D. (2025). The Synergic Inhibition of Wilforlide A With Cisplatin in Lung Cancer Is Mediated Through Caspase‐3 and NFκB Signaling. IUBMB Life. https://doi.org/10.1002/iub.70043

Vancouver

Peng Z, Xiao X, Lu X, Cao D, Fang H, Yang Z, et al. The Synergic Inhibition of Wilforlide A With Cisplatin in Lung Cancer Is Mediated Through Caspase‐3 and NFκB Signaling. IUBMB Life. 2025. doi:10.1002/iub.70043

BibTeX
@article{Peng2025,
  author = {Peng, Zhonglu and Xiao, Xiang and Lu, Xinyi and Cao, Dong and Fang, Huilong and Yang, Zhiying and He, Dongyang},
  title = {The Synergic Inhibition of Wilforlide A With Cisplatin in Lung Cancer Is Mediated Through Caspase‐3 and NFκB Signaling},
  journal = {IUBMB Life},
  year = {2025},
  doi = {10.1002/iub.70043}
}
Kostenlos starten →